Pfizer Stock Price Forecast & prediction 2025, 2026, 2027 to 2030: Today, we will provide a concise analysis of Pfizer’s stock price forecasts for 2025, 2026, 2027 to 2030. By examining current market trends and Pfizer’s historical performance, we aim to highlight key factors shaping its future outlook. As a major player in pharmaceuticals and biotechnology, Pfizer’s financial prospects are heavily influenced by its pipeline of innovative treatments, global healthcare demand, and strategic partnerships.
This analysis covers both fundamental and technical aspects of Pfizer’s performance, offering insights into its growth potential. With a focus on expanding vaccine and therapeutic portfolios, as well as emerging market opportunities, understanding Pfizer’s trajectory is essential for investors following the healthcare sector’s evolution.
Overview of Pfizer Inc.
What is Pfizer Inc.?
Pfizer Inc. is a leading American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in Brooklyn, New York, by German entrepreneurs Charles Pfizer and Charles F. Erhart, the company has grown to become one of the largest pharmaceutical firms worldwide by revenue. Pfizer develops and manufactures a wide range of healthcare products, including vaccines, medicines, and therapies across numerous therapeutic areas, serving patients and healthcare providers globally.
Key Features of Pfizer Inc.:
- Business Model: Revenue from prescription medicines and over-the-counter products, driven by strong R&D in innovative drugs and vaccines.
- Core Divisions: Focus on innovative medicines, oncology, and established products, supported by subsidiaries like Seagen and Hospira.
- Clientele: Global reach, serving healthcare systems, governments, and pharmacies worldwide.
- Market Position: Leading pharmaceutical player, leveraging a diverse portfolio and strategic partnerships.
- Revenue and Stock Performance: Significant growth from vaccine demand and new therapies, with a workforce of 88,000 led by CEO Albert Bourla.
| Attribute | Details |
|---|---|
| Website | pfizer.com |
| CEO | Albert Bourla (since January 1, 2019) |
| Founded | 1849, Brooklyn, New York, United States |
| Headquarters | The Spiral, New York City, New York, United States |
| Number of Employees | 88,000 (2023) |
| Stock Listing | NYSE: PFE |
| Key Operations | Pharmaceutical and biotech research, drug manufacturing, vaccine development |
| Subsidiaries | Seagen, Hospira, Pfizer Pfe, Spol. S R.O., Pfizer A |
| Notable Initiatives | Expansion of vaccine portfolio, R&D in oncology and rare diseases |
Current Market Overview of Pfizer Stock Price
As of November 2024, Pfizer’s stock has a market cap of ₹15.92K crores, opening at $28.48 with a high of $28.54 and a low of $28.05. The P/E ratio stands at 37.96, and the dividend yield is 5.98%, supported by a CDP score of A-. The stock’s 52-week high is $31.54, while the low is $25.20.
In market performance, Pfizer is down 0.21 points (-0.74%) today, with a 5-day decline of 0.51 points (-1.78%) and a monthly decrease of 0.49 points (-1.71%). Year-to-date, it has dropped 1.64 points (-5.52%), and over the past year, it is down 3.09 points (-9.91%). Despite a five-year decline of 7.01 points (-19.97%), Pfizer shows a strong all-time return of +26.51 points (1,677.85%).
Pfizer Stock Price Fundamental Data
- Open: $28.48
- High: $28.54
- Low: $28.05
- Market Cap: 15.92K Cr
- P/E Ratio: 37.96
- Dividend Yield: 5.98%
- CDP Score: A-
- 52-Week High: $31.54
- 52-Week Low: $25.20
The Market Position of Pfizer Stock as of November 2024
| Time | Returns of Pfizer Stock |
|---|---|
| Today | -0.21 (-0.74%) |
| Past 5 Days | -0.51 (-1.78%) |
| Past Month | -0.49 (-1.71%) |
| Past 6 Months | -0.07 (-0.25%) |
| Year to Date | -1.64 (-5.52%) |
| Past Year | -3.09 (-9.91%) |
| Past 5 Years | -7.01 (-19.97%) |
| All Time | +26.51 (1,677.85%) |
Pfizer Stock Price Prediction in 2025
Stock price prediction for Pfizer in 2025 is projected to range between $35 and $41, reflecting moderate growth potential throughout the year. November is expected to be the most bullish month, reaching up to $37, indicating a strong upward trend.
| Month | Minimum Price | Maximum Price |
|---|---|---|
| January | $39 | $41 |
| February | $40 | $42 |
| March | $40 | $42 |
| April | $39 | $41 |
| May | $38 | $40 |
| June | $38 | $41 |
| July | $37 | $40 |
| August | $35 | $38 |
| September | $34 | $36 |
| October | $32 | $35 |
| November | $35 | $37 |
| December | $36 | $38 |
Pfizer Stock Price Prediction in 2026
Stock price prediction for Pfizer in 2026 shows a bearish outlook, with prices expected to fluctuate between $28 and $40. January could see the highest point at $40, while October may reach a low of $28.
| Month | Minimum Price | Maximum Price |
|---|---|---|
| January | $38 | $40 |
| February | $36 | $39 |
| March | $36 | $39 |
| April | $35 | $38 |
| May | $35 | $37 |
| June | $34 | $36 |
| July | $32 | $35 |
| August | $30 | $32 |
| September | $29 | $31 |
| October | $28 | $30 |
| November | $30 | $32 |
| December | $31 | $33 |
Pfizer Stock Price Prediction in 2027
Stock price prediction for Pfizer in 2027 suggests a continued downtrend, with prices anticipated to vary between $23 and $31. December could reach the highest price of $27, indicating a challenging investment environment.
| Month | Minimum Price | Maximum Price |
|---|---|---|
| January | $29 | $31 |
| February | $28 | $30 |
| March | $27 | $29 |
| April | $27 | $29 |
| May | $27 | $29 |
| June | $26 | $28 |
| July | $26 | $27 |
| August | $25 | $27 |
| September | $24 | $26 |
| October | $23 | $25 |
| November | $24 | $26 |
| December | $25 | $27 |
Pfizer Stock Price Prediction in 2028
Stock price prediction for Pfizer in 2028 shows a continued decline, with prices expected to range from $19 to $26. December is anticipated to be the peak month, with the stock reaching $22, signaling a gradual recovery.
| Month | Minimum Price | Maximum Price |
|---|---|---|
| January | $25 | $26 |
| February | $24 | $25 |
| March | $23 | $25 |
| April | $22 | $24 |
| May | $22 | $23 |
| June | $21 | $23 |
| July | $21 | $22 |
| August | $20 | $22 |
| September | $19 | $21 |
| October | $19 | $20 |
| November | $20 | $21 |
| December | $21 | $22 |
Pfizer Stock Price Prediction in 2029
Stock price prediction for Pfizer in 2029 suggests a further decline, with prices anticipated to range from $16 to $21. The highest point is expected in January, reaching $21, reflecting a continued bearish outlook.
| Month | Minimum Price | Maximum Price |
|---|---|---|
| January | $20 | $21 |
| February | $19 | $20 |
| March | $19 | $20 |
| April | $18 | $19 |
| May | $18 | $19 |
| June | $18 | $19 |
| July | $17 | $18 |
| August | $17 | $18 |
| September | $16 | $17 |
| October | $16 | $17 |
| November | $17 | $18 |
| December | $18 | $19 |
Pfizer Stock Price Prediction in 2030
Stock price prediction for Pfizer in 2030 is expected to show a recovery, with prices projected to reach a high of $32 in January, with fluctuations ranging down to $25 in October. This forecast suggests potential for growth.
| Month | Minimum Price | Maximum Price |
|---|---|---|
| January | $29 | $32 |
| February | $27 | $31 |
| March | $28 | $32 |
| April | $28 | $33 |
| May | $29 | $32 |
| June | $28 | $32 |
| July | $29 | $31 |
| August | $27 | $29 |
| September | $26 | $28 |
| October | $25 | $28 |
| November | $28 | $30 |
| December | $30 | $32 |
Pfizer Financial Health and Performance Analysis (FY 2020 – FY 2024)
| Metric | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 2,335.67 | 2,319.67 | 2,673.64 | 2,525.81 | 2,373.68 |
| Total Revenue Growth (%) | 3.86% | -0.69% | 15.26% | -5.53% | -6.02% |
| Total Expenses (Cr) | 1,693.18 | 1,650.95 | 1,900.75 | 1,734.80 | 1,635.56 |
| Total Expenses Growth (%) | 6.56% | -2.49% | 15.13% | -8.73% | -5.72% |
| Profit after Tax (PAT) (Cr) | 509.13 | 497.61 | 612.56 | 623.93 | 551.33 |
| PAT Growth (%) | 18.66% | -2.26% | 23.10% | 1.86% | -11.64% |
| Operating Profit Margin (%) | 30.36% | 30.54% | 30.00% | 33.17% | 34.35% |
| Net Profit Margin (%) | 23.66% | 22.22% | 23.46% | 25.73% | 25.13% |
| Basic EPS (₹) | 111.28 | 108.77 | 133.89 | 128.50 | 120.51 |
Performance Highlights
- Revenue Trends: Pfizer experienced a decline in total revenue, dropping to ₹2,373.68 crore in FY 2024, a decrease of 6.02% compared to the previous year, reflecting challenges in sustaining growth.
- Expense Management: Total expenses also decreased to ₹1,635.56 crore in FY 2024, a reduction of 5.72%, indicating a focus on cost management amid declining revenues.
- Profitability: The profit after tax fell to ₹551.33 crore, representing a decline of 11.64%, highlighting pressures on profitability in a challenging market environment.
- Profit Margins: Operating profit margins improved to 34.35% in FY 2024, reflecting better operational efficiency, while net profit margins slightly decreased to 25.13%.
- Earnings per Share (EPS): Basic EPS decreased to ₹120.51 in FY 2024, down from ₹128.50 in FY 2023, reflecting the overall decline in profitability.
How to Invest in Pfizer Inc.
- Select a Broker: Choose a reputable brokerage platform that offers Pfizer (PFE) shares.
- Open a Trading Account: Register for a trading account and, if necessary, a Demat account to hold shares.
- Complete KYC: Fulfill Know Your Customer (KYC) requirements by providing valid ID and address proof.
- Fund Your Account: Deposit funds into your trading account to enable purchases.
- Search for Pfizer: Use the ticker “PFE” to locate Pfizer shares on your trading platform.
- Place an Order: Decide on the number of shares and choose between a market or limit order based on your preference.
- Confirm the Transaction: Review your order details carefully and confirm the purchase.
- Monitor Your Investment: Keep track of Pfizer’s performance, market conditions, and industry trends for strategic decision-making.
Pfizer Stock Price Forecast for the Next 5 Years
Pfizer Inc. is expected to navigate a challenging landscape over the next five years, influenced by its pipeline of innovative pharmaceuticals, ongoing research and development initiatives, and the competitive dynamics within the healthcare sector. The following stock price forecast for Pfizer reflects anticipated market conditions, growth potential from new product launches, and the company’s strategic focus on expanding its portfolio.
| Year | Minimum Price | Maximum Price |
|---|---|---|
| 2025 | $30 | $36 |
| 2026 | $32 | $40 |
| 2027 | $34 | $42 |
| 2028 | $36 | $45 |
| 2029 | $38 | $48 |
Pfizer Inc. Shareholding Pattern
The shareholding pattern of Pfizer Inc. demonstrates a stable and well-distributed ownership structure, reflecting investor confidence in the company’s growth prospects and strategic direction. The data highlights the dominance of promoters, alongside a growing presence of institutional investors and mutual funds, indicating strong support for Pfizer’s future initiatives.
| Category | 30 Sep 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Promoters | 63.92% | 63.92% | 63.92% | 63.92% |
| Pledge | 0.00% | 0.00% | 0.00% | 0.00% |
| FII | 3.54% | 3.21% | 3.32% | 3.03% |
| DII | 16.02% | 15.82% | 15.31% | 15.12% |
| Mutual Funds | 10.43% | 8.32% | 7.72% | 7.61% |
| Others | 16.51% | 17.05% | 17.45% | 17.92% |
